Clinical Trial

A Study of LY4355756 in Healthy Participants

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of the study is to assess how LY4355756 is absorbed by the body and how safe it is to healthy participants. There will be four inpatient stays at the clinical research unit (CRU). For Part A there will be 5 continuous days, Part B 22 continuous days, Part C 5 continuous days in each of the 3 periods, and Part D 18 continuous days in the CRU.
Trial Details
NCT Number NCT07765498
Lead Sponsor Eli Lilly and Company
Conditions Healthy
Enrollment 123 participants
Start Date 2026-08
Primary Completion 2027-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-14